Display options
Cite
Petkov VI, Miller DP, Howlader N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016;2:16017doi: 10.1038/npjbcancer.2016.17.
Petkov, V. I., Miller, D. P., Howlader, N., Gliner, N., Howe, W., Schussler, N., Cronin, K., Baehner, F. L., Cress, R., Deapen, D., Glaser, S. L., Hernandez, B. Y., Lynch, C. F., Mueller, L., Schwartz, A. G., Schwartz, S. M., Stroup, A., Sweeney, C., Tucker, T. C., Ward, K. C., Wiggins, C., Wu, X. C., Penberthy, L., & Shak, S. (2016). Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ breast cancer, 216017. https://doi.org/10.1038/npjbcancer.2016.17
Petkov, Valentina I, et al. "Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study." NPJ breast cancer vol. 2 (2016): 16017. doi: https://doi.org/10.1038/npjbcancer.2016.17
Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016 Jun 08;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016. PMID: 28721379; PMCID: PMC5515329.
Copy Download .nbib Format: NLM
Share it on

NPJ Breast Cancer. 2016 Jun 08;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016.

Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.

NPJ breast cancer

Valentina I Petkov, Dave P Miller, Nadia Howlader, Nathan Gliner, Will Howe, Nicola Schussler, Kathleen Cronin, Frederick L Baehner, Rosemary Cress, Dennis Deapen, Sally L Glaser, Brenda Y Hernandez, Charles F Lynch, Lloyd Mueller, Ann G Schwartz, Stephen M Schwartz, Antoinette Stroup, Carol Sweeney, Thomas C Tucker, Kevin C Ward, Charles Wiggins, Xiao-Cheng Wu, Lynne Penberthy, Steven Shak

Affiliations

  1. National Cancer Institute, Bethesda, MD, USA.
  2. Genomic Health, Inc., Redwood City, CA, USA.
  3. IMS, Inc., Calverton, MD, USA.
  4. University of California, San Francisco, CA, USA.
  5. Public Health Institute, Cancer Registry of Greater California, Sacramento, CA, USA.
  6. University of Southern California, Los Angeles, CA, USA.
  7. Cancer Prevention Institute of California, Fremont, CA, USA.
  8. Stanford Cancer Institute, Stanford, CA, USA.
  9. University of Hawaii Cancer Center, Honolulu, HI, USA.
  10. Department of Epidemiology, University of Iowa, Iowa City, IA, USA.
  11. Connecticut Tumor Registry, Connecticut Department of Public Health, Hartford, CT, USA.
  12. Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  13. Cancer Surveillance System, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  14. Rutgers School of Public Health, Piscataway, NJ, USA.
  15. Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  16. Utah Cancer Registry, Department of Internal Medicine, and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  17. University of Kentucky, Markey Cancer Center, Lexington, KY, USA.
  18. Emory University, Atlanta, GA, USA.
  19. New Mexico Tumor Registry, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.
  20. Louisiana State University Health Sciences Center, New Orleans, LA, USA.

PMID: 28721379 PMCID: PMC5515329 DOI: 10.1038/npjbcancer.2016.17

Abstract

The 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recurrence Score results and clinical covariates, the National Cancer Institute collaborated with Genomic Health and 14 population-based registries in the the Surveillance, Epidemiology, and End Results (SEER) Program to electronically supplement cancer surveillance data with Recurrence Score results. The prespecified primary analysis cohort was 40-84 years of age, and had node-negative, HR+, HER2-negative, nonmetastatic disease diagnosed between January 2004 and December 2011 in the entire SEER population, and Recurrence Score results (

Conflict of interest statement

D.P.M., N.G., F.L.B., and S.S. are employees of Genomic Health. The remaining authors declare no conflict of interest.

References

  1. Breast Cancer Res Treat. 2011 Apr;126(3):797-802 - PubMed
  2. JAMA. 2001 Feb 21;285(7):885-92 - PubMed
  3. Oncologist. 2011;16(11):1520-6 - PubMed
  4. Am J Manag Care. 2010 Jun;16(6):467-71 - PubMed
  5. Breast Cancer Res. 2006;8(3):R25 - PubMed
  6. J Clin Oncol. 2010 Apr 10;28(11):1829-34 - PubMed
  7. PLoS One. 2015 May 28;10(5):e0128345 - PubMed
  8. J Clin Oncol. 2010 Apr 1;28(10):1671-6 - PubMed
  9. Eur J Cancer. 2010 Jun;46(9):1528-36 - PubMed
  10. Ann Surg Oncol. 2015 Apr;22(4):1102-10 - PubMed
  11. J Clin Oncol. 2010 Oct 1;28(28):4300-6 - PubMed
  12. J Clin Oncol. 2006 Aug 10;24(23):3726-34 - PubMed
  13. N Engl J Med. 2004 Dec 30;351(27):2817-26 - PubMed
  14. Med Care. 2016 Sep;54(9):e55-64 - PubMed
  15. J Oncol Pract. 2007 Jul;3(4):182-6 - PubMed
  16. J Natl Cancer Inst. 2010 Oct 20;102(20):1584-98 - PubMed
  17. JAMA. 2012 Feb 8;307(6):590-7 - PubMed
  18. CA Cancer J Clin. 2016 Jul;66(4):290-308 - PubMed
  19. Cancer Causes Control. 2014 Jan;25(1):81-92 - PubMed
  20. J Clin Oncol. 2005 Feb 1;23(4):783-91 - PubMed
  21. J Clin Oncol. 2016 Jul 10;34(20):2341-9 - PubMed
  22. Lancet Oncol. 2010 Jan;11(1):55-65 - PubMed
  23. Lancet. 2005 May 14-20;365(9472):1687-717 - PubMed
  24. Breast Cancer Res Treat. 2011 Jun;127(3):729-38 - PubMed
  25. J Clin Oncol. 2009 Jun 10;27(17):2881-5 - PubMed
  26. J Clin Oncol. 2006 Mar 20;24(9):1342-9 - PubMed
  27. N Engl J Med. 2015 Nov 19;373(21):2005-14 - PubMed

Publication Types

Grant support